{
    "clinical_study": {
        "@rank": "154832", 
        "arm_group": [
            {
                "arm_group_label": "Erlotinib and Chemotherapy", 
                "arm_group_type": "Experimental", 
                "description": "Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance"
            }, 
            {
                "arm_group_label": "Chemotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Chemotherapy for four to six cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether continuing erlotinib beyond disease\n      progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR\n      mutant disease or who have responded to EGFR TKI."
        }, 
        "brief_title": "Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Phase II randomised, multicenter study to assess the efficacy and safety of continuing\n      erlotinib in addition to chemotherapy versus chemotherapy alone in patients who have EGFR\n      mutant or EGFR TKI responsive NSCLC and have progressed on EGFR TKI."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed stage IIIB/IV NSCLC.\n\n          -  Investigator confirmed progression according RECIST 1.1 during EGFR TKI treatment\n             within 28  days of the randomization\n\n          -  Activating mutation (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q) in the EGFR\n             gene or have had at least partial response with EGFR TKI lasting \u2265 6 months\n\n          -  Performance status: WHO 0-2\n\n          -  Measurable disease according to RECIST 1.1\n\n          -  Patients must be able to comply with study treatments\n\n          -  Women with child-bearing potential and men with reproductive potential must be\n             willing to practice acceptable methods of birth control during the study\n\n          -  Neutrophils \u2265 1'000/\u03bcl, Platelets \u2265 100'000/\u03bcl, Alanine amino transferase  \u2264 2.5 \u00d7\n             Upper limit of normal (ULN) (< 5 \u00d7 ULN if liver metastases), Alkaline phosphatase \u2264\n             2.5 \u00d7 ULN (< 5 \u00d7 ULN if liver metastases), Serum bilirubin  \u2264 1.5 \u00d7 ULN, Serum\n             Creatinine \u2264 1.5 \u00d7 ULN.\n\n          -  Patient must be able to comply with the protocol\n\n        Exclusion Criteria:\n\n          -  RECIST 1.1 defined disease progression for more than 28 days while on previous EGFR\n             TKI treatment.\n\n          -  Patient has been treated with any investigational agent for any indication within 4\n             weeks of study treatment.\n\n          -  Patient has history of hypersensitivity or intolerance to erlotinib or gefitinib.\n\n          -  Patient has history of hypersensitivity or intolerance to chemotherapeutic agents\n             used in the study.\n\n          -  Patient with symptomatic central nervous system metastases\n\n          -  Patient has known active hepatitis B or C, or HIV infection\n\n          -  Pregnant or breastfeeding.\n\n          -  Patient with uncontrolled undercurrent illness or circumstances that could limit\n             compliance with the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064491", 
            "org_study_id": "ETAP", 
            "secondary_id": "2013-002049-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Erlotinib and Chemotherapy", 
                "intervention_name": "Erlotinib", 
                "intervention_type": "Drug", 
                "other_name": "Tarceva"
            }, 
            {
                "arm_group_label": [
                    "Erlotinib and Chemotherapy", 
                    "Chemotherapy"
                ], 
                "intervention_name": "Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": "Cisplatin, Carboplatin, Docetaxel, Paclitaxel, Pemetrexed"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Erlotinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Non-small cell lung cancer", 
            "EGFR mutant", 
            "Erlotinib", 
            "Treatment Beyond Progression"
        ], 
        "lastchanged_date": "February 14, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jukka.lojander@hus.fi", 
                    "last_name": "Jukka Lojander, M.D., Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Espoo", 
                        "country": "Finland"
                    }, 
                    "name": "Helsinki University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jukka Lojander, M.D., Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "aija.knuuttila@hus.fi", 
                    "last_name": "Aija Knuuttila, M.D., Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland"
                    }, 
                    "name": "Helsinki University Hospital"
                }, 
                "investigator": {
                    "last_name": "Aija Knuuttila, M.D., Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jussi.koivunen@ppshp.fi", 
                    "last_name": "Jussi P Koivunen, M.D., Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland"
                    }, 
                    "name": "Oulu University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jussi P Koivunen, M.D., Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "matti.pietilainen@satshp.fi", 
                    "last_name": "Matti Pietil\u00e4inen, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Pori", 
                        "country": "Finland"
                    }, 
                    "name": "Pori Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Matti Pietil\u00e4inen, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jarkko.ahvonen@pshp.fi", 
                    "last_name": "Jarkko Ahvonen, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Tampere", 
                        "country": "Finland"
                    }, 
                    "name": "Tampere University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jarkko Ahvonen, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "taneli.saariaho@tyks.fi", 
                    "last_name": "Taneli Saariaho, M.D., Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Turku", 
                        "country": "Finland"
                    }, 
                    "name": "Turku University Hopital"
                }, 
                "investigator": {
                    "last_name": "Taneli Saariaho, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "antti.jekunen@vshp.fi", 
                    "last_name": "Antti Jekunen, M.D., Ph.D"
                }, 
                "facility": {
                    "address": {
                        "city": "Vaasa", 
                        "country": "Finland"
                    }, 
                    "name": "Vaasa Central Hospital"
                }, 
                "investigator": {
                    "last_name": "Antti Jekunen, M.D., Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC", 
        "overall_contact": {
            "email": "jussi.koivunen@ppshp.fi", 
            "last_name": "Jussi P Koivunen, M.D., Ph.D", 
            "phone": "35883153789"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Finnish Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival of the whole study population and in the strata 1-2", 
            "safety_issue": "No", 
            "time_frame": "An expected average of 36 weeks after last subject enrolled into our study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064491"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "An expected average of 52 weeks after last subject enrolled into our study"
            }, 
            {
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "An expected average of 36 weeks after last subject enrolled into our study"
            }, 
            {
                "measure": "Rate of non-progression at 9 and 18 weeks", 
                "safety_issue": "No", 
                "time_frame": "18 weeks after date of randomization of a last patient"
            }, 
            {
                "description": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "measure": "Safety and toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "An expected average of 52 weeks after last subject enrolled into our study"
            }
        ], 
        "source": "Finnish Lung Cancer Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Finnish Lung Cancer Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}